Konferenzen  >  Medizin & Gesundheitswesen  >  Onkologie  >  Virtuelle Veranstaltung

The European Association for Cancer Research (EACR) and AstraZeneca

Epigenetic control is essential for development and differentiation, and this control mechanism is very frequently deregulated in cancer. Several small molecule inhibitors have been developed in recent years that have either been approved for clinical use or are in preclinical and clinical trials. This conference will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.

Tel.: [N/A];     Email: hannah.barrs@eacr.org

epigenetics, molecule inhibitors, epigenetic proteins in cancer, monotherapies, combination therapies, immune checkpoint inhibitors, drug discovery, drug sensitivity, chemoresistance, genetically targeted cancer therapy, novel epigenetic targets, drug resistance, clinical cancer trials, cancer research, oncology

The European Association for Cancer Research (EACR), in conjunction with the European Molecular Biology Organisation (EMBO)

The EACR, in partnership with EMBO, is launching a new virtual conference for those working in cancer research in an academic environment who are considering at some point in the future taking their research private by starting their own company. Wherever you are in your academic career, if you think you might like to commercialise your research in the future then this conference is for you!

This conference aims to act as a ‘starter pack’ and will encompass a collection of powerful personal examples, advice from people who have done it, and representatives of relevant industries. It aims to inform participants of the steps that need to be considered when making the decision to commercialise academic research and the opportunities available.

The target audience for this conference is researchers working in academia who are considering commercialising their research, whether now or in the future.

Conference Officer: Chris Iliffe;     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer research, oncology, research funding, legal advice for cancer researchers, privatising research, moving from academia to business, career progression, cancer research careers

The European Association for Cancer Research (EACR)

Discover the hidden world of cancer signaling circuits with leading experts at this EACR Virtual Conference! This conference will focus on basic mechanisms controlling cancer cell signaling circuits at the epigenome, transcriptome, proteome, and phosphoproteome levels. The talks will also focus on therapeutic targeting of cancer cell signaling circuits by conventional and emerging pharmacological strategies, and the mechanistic aspects of post translational and transcriptional regulation of cancer cell signaling, as well as large OMICS-based global understanding of cancer cell signaling circuits.

The target audience for this conference is: scientists in academia and industry who are interested in the most recent developments in non-genetic signaling mechanisms and their roles in cancer progression and therapy resistance.

Conference Officer: Chris Iliffe;     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer signaling circuits, cancer tissue phenotypes, targeted cancer therapies, cancer therapy resistance, non-genetic signaling rewiring, post-translational protein regulation, transcriptional gene regulation, cancer progression, epigenomics, transcriptomics, proteomics, phosphoproteomics, kinases and phosphatases, cancer cell plasticity, cancer research, oncology

Translationale Medizin, Klinische Studien,    Genomforschung und Bioinformatik